PPARG and Bjornstad syndrome: Pretreatment with rosiglitazone, which promotes placental synthesis of peroxisome proliferator-activated receptor-γ (PPARγ) similarly attenuates responsiveness to LPS-induced PTD, in association with suppressed NFκB signaling and reduced synthesis of TNF, IL1, IL6 and other pro-inflammatory chemokines57.